- Home
- NHS vs RCEL Comparison
NHS vs RCEL Comparison
Compare NHS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHS
- RCEL
- Stock Information
- Founded
- NHS 2003
- RCEL 2020
- Country
- NHS United States
- RCEL United States
- Employees
- NHS N/A
- RCEL N/A
- Industry
- NHS Trusts Except Educational Religious and Charitable
- RCEL Medical/Dental Instruments
- Sector
- NHS Finance
- RCEL Health Care
- Exchange
- NHS Nasdaq
- RCEL Nasdaq
- Market Cap
- NHS 221.5M
- RCEL 274.7M
- IPO Year
- NHS N/A
- RCEL N/A
- Fundamental
- Price
- NHS $8.09
- RCEL $10.47
- Analyst Decision
- NHS
- RCEL Hold
- Analyst Count
- NHS 0
- RCEL 3
- Target Price
- NHS N/A
- RCEL $15.00
- AVG Volume (30 Days)
- NHS 111.8K
- RCEL 89.6K
- Earning Date
- NHS 01-01-0001
- RCEL 11-07-2024
- Dividend Yield
- NHS 13.44%
- RCEL N/A
- EPS Growth
- NHS N/A
- RCEL N/A
- EPS
- NHS N/A
- RCEL N/A
- Revenue
- NHS N/A
- RCEL $54,139,000.00
- Revenue This Year
- NHS N/A
- RCEL $40.31
- Revenue Next Year
- NHS N/A
- RCEL $45.42
- P/E Ratio
- NHS N/A
- RCEL N/A
- Revenue Growth
- NHS N/A
- RCEL 32.53
- 52 Week Low
- NHS $6.95
- RCEL $7.51
- 52 Week High
- NHS $9.17
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- NHS 39.33
- RCEL 53.73
- Support Level
- NHS $8.29
- RCEL $9.74
- Resistance Level
- NHS $8.56
- RCEL $10.90
- Average True Range (ATR)
- NHS 0.15
- RCEL 0.46
- MACD
- NHS -0.04
- RCEL -0.05
- Stochastic Oscillator
- NHS 0.00
- RCEL 53.28
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.